• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

AZD2014

CAS No. 1009298-59-2

AZD2014 ( Vistusertib )

产品货号. M10062 CAS No. 1009298-59-2

AZD2014 是一种新型 mTOR 抑制剂,无细胞测定中的 IC50 为 2.8 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥348 有现货
5MG ¥551 有现货
10MG ¥964 有现货
25MG ¥1490 有现货
50MG ¥2017 有现货
100MG ¥3216 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    AZD2014
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    AZD2014 是一种新型 mTOR 抑制剂,无细胞测定中的 IC50 为 2.8 nM。
  • 产品描述
    AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). Phase 2.(In Vitro):The inhibitory effects of Vistusertib (AZD2014) are measured against isolated recombinant mTOR enzyme (IC50?of 2.81 nM) as well as in cellular assays measuring both mTORC1 and mTORC2 activities. In MDAMB468 cells, Vistusertib (AZD2014) decreases the phosphorylation of the mTORC1 substrate ribosomal protein S6 (Ser235/236) with a mean IC50?value of 210 nM and the mTORC2 substrate AKT (Ser473) with a mean IC50?value of 78 nM.(In Vivo):Vistusertib (AZD2014) induces dose-dependent tumor growth inhibition in several xenograft and primary explant models. The antitumor activity of Vistusertib (AZD2014) is associated with modulation of both mTORC1 and mTORC2 substrates, consistent with its mechanism of action. The pharmacokinetics of Vistusertib (AZD2014) in mice is tested upon administration of doses between 7.5 and 15 mg/kg. A dose-dependent increase in Cmax and AUC is observed following single dose and repeat dosing of AZD2014: Cmax range from 1 to 16 μM and AUC range from 220 to 5,042 μM·h across this dose range. The pharmacodynamic effect of Vistusertib (AZD2014) against an mTORC1 biomarker (phosphorylation of S6) and an mTORC2 biomarker (phosphorylation of AKT) is assessed in SCID mice bearing MCF7 xenografts following administration of 3.75, 7.5, and 15 mg/kg AZD2014. There is a good relationship between the drug plasma concentrations and biomarker levels (estimated p-AKT IC50 of 0.119 μM total, 53% SE, and estimated p-S6 IC50 0.392 μM, 28.8% SE).
  • 体外实验
    ——
  • 体内实验
    ——
  • 同义词
    Vistusertib
  • 通路
    PI3K/Akt/mTOR signaling
  • 靶点
    Akt
  • 受体
    P-Akt (S473)| mTOR| PI3Kα| pS6 (S235/236)
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1009298-59-2
  • 分子量
    462.54
  • 分子式
    C25H30N6O3
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO: 38 mg/mL (82.15 mM)
  • SMILES
    O=C(NC)C1=CC=CC(C2=CC=C3C(N4[C@@H](C)COCC4)=NC(N5[C@@H](C)COCC5)=NC3=N2)=C1
  • 化学全称
    3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Sylvie M. Guichard, et al. Y Research: April 15, 2012; Volume 72, Issue 8, Supplement
产品手册
关联产品
  • Perifosine

    一种口服生物可利用的烷基磷脂,在多种人类肿瘤模型中在体外和体内表现出显着的抗增殖活性;作为 Akt 抑制剂和 PI3K 抑制剂。

  • AZD-5363

    AZD5363 是一种新型吡咯并嘧啶衍生化合物,可抑制所有 AKT 异构体 (IC50 <10 nM)。

  • Akt1Akt2-IN-17

    一种有效的选择性 Akt1 和 Akt2 双重抑制剂,IC50 分别为 3.5 nM 和 42 nM。